JNJ’s debt‑to‑equity ratio remains conservative, a factor integrated into bullish forecast models that anticipate ongoing capacity for acquisitions and product development. In such a macroeconomic environment, the notion of acquiring the best “forever stocks” might appear challenging. That said, although investors may gravitate toward riskier options with bigger potential returns, it is crucial to recognize that long-term stock investments have their worth and importance. Before you consider Johnson & Johnson, you'll want to hear this. Macro forecasts for the healthcare industry remain strong, with aging population trends benefiting JNJ’s long‑term earnings. This underpins a steady JNJ stock forecast despite broader market uncertainty.